Potential Benefits of Incretins Beyond Glycemic Control in T2D

supported by an educational grant from Eli Lilly and Company |

13:00 – 13:15Show Me the Data:
Clinical Trial Refresher | New Evidence | Potential Benefits
Michael A. Nauck (GER)
13:15 – 13:25Questions and answersMichael A. Nauck (GER)
13:25 – 13:45

Case Study Central:
Clinical Implications | Safety/Tolerability, Dose Escalation, Side Effect Management

Bernhard Ludvik (AUT)
Juan Pablo Frias (USA)
13:45 – 13:50Questions and answersBernhard Ludvik (AUT)
Juan Pablo Frias (USA)
13:50 – 14:00Ask Me Anything:
Incretins Edition
All faculty

Provided by Medical Learning Institute, Inc. and Endocrine Society